

Lisa Coussens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8324817/publications.pdf>

Version: 2024-02-01

75
papers

23,002
citations

61984

43
h-index

91884

69
g-index

81
all docs

81
docs citations

81
times ranked

33009
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging. <i>Nature Methods</i> , 2022, 19, 311-315. | 19.0 | 102 |
| 2 | Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma. <i>Npj Precision Oncology</i> , 2022, 6, 10. | 5.4 | 23 |
| 3 | An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. <i>Cell Reports Medicine</i> , 2022, 3, 100525. | 6.5 | 22 |
| 4 | Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 440-462. | 46.4 | 58 |
| 5 | MITI minimum information guidelines for highly multiplexed tissue images. <i>Nature Methods</i> , 2022, 19, 262-267. | 19.0 | 37 |
| 6 | Early detection of cancer. <i>Science</i> , 2022, 375, eaay9040. | 12.6 | 291 |
| 7 | T-cell Dysfunction upon Expression of MYC with Altered Phosphorylation at Threonine 58 and Serine 62. <i>Molecular Cancer Research</i> , 2022, 20, 1151-1165. | 3.4 | 0 |
| 8 | Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. <i>Clinical Cancer Research</i> , 2022, 28, 903-914. | 7.0 | 14 |
| 9 | Novel Therapeutics Modulate Cardiac Leukocyte Populations Following Myocardial Infarction. <i>FASEB Journal</i> , 2022, 36, . | 0.5 | 0 |
| 10 | Deciphering the Immune Complexity in Esophageal Adenocarcinoma and Pre-Cancerous Lesions With Sequential Multiplex Immunohistochemistry and Sparse Subspace Clustering Approach. <i>Frontiers in Immunology</i> , 2022, 13, . | 4.8 | 6 |
| 11 | A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs. <i>Nature Biotechnology</i> , 2022, 40, 1823-1833. | 17.5 | 17 |
| 12 | Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. <i>Nature Materials</i> , 2021, 20, 548-559. | 27.5 | 125 |
| 13 | Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1069-1081. | 7.0 | 75 |
| 14 | Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. <i>Cancer Discovery</i> , 2021, 11, 2014-2031. | 9.4 | 79 |
| 15 | High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 40. | 5.0 | 18 |
| 16 | Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. <i>Annals of Oncology</i> , 2021, 32, 600-608. | 1.2 | 69 |
| 17 | Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4574-4586. | 7.0 | 82 |
| 18 | Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1211-1223. | 1.1 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Abstract CT005: T cell inflammation in the tumor microenvironment after agonist CD40 antibody: Clinical and translational results of a neoadjuvant clinical trial. , 2021, , . | | 0 |
| 20 | Multimomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. <i>Npj Precision Oncology</i> , 2021, 5, 92. | 5.4 | 11 |
| 21 | Redirecting tumor macrophage activity to fight cancer: Make room for the next era of anti-cancer drugs. <i>Cancer Cell</i> , 2021, 39, 1300-1302. | 16.8 | 3 |
| 22 | Spatial Profiles of Intratumoral PD-1+ Helper T Cells Predict Prognosis in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 769534. | 4.8 | 12 |
| 23 | Abstract PO-095: A cancer cell-intrinsic GOT2-PPAR α axis suppresses antitumor immunity. , 2021, , . | | 0 |
| 24 | Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers. <i>Cancer Immunology Research</i> , 2020, 8, 131-145. | 3.4 | 21 |
| 25 | Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer. <i>Cancer Discovery</i> , 2020, 10, 1489-1499. | 9.4 | 60 |
| 26 | Zena Werb 1945â€“2020. <i>Nature Cancer</i> , 2020, 1, 753-754. | 13.2 | 1 |
| 27 | High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers. <i>Methods in Enzymology</i> , 2020, 635, 1-20. | 1.0 | 57 |
| 28 | Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3578-3588. | 7.0 | 76 |
| 29 | The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. <i>Cell</i> , 2020, 181, 236-249. | 28.9 | 334 |
| 30 | Innate $\gamma\delta$ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming. <i>Cancer Discovery</i> , 2019, 9, 1288-1305. | 9.4 | 19 |
| 31 | Clinical Response of Live-Attenuated, <i>Listeria monocytogenes</i> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2019, 25, 5787-5798. | 7.0 | 72 |
| 32 | Macrophages and Metabolism in the Tumor Microenvironment. <i>Cell Metabolism</i> , 2019, 30, 36-50. | 16.2 | 933 |
| 33 | The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. <i>Nature Communications</i> , 2019, 10, 4682. | 12.8 | 123 |
| 34 | Robust Cell Detection and Segmentation for Image Cytometry Reveal Th17 Cell Heterogeneity. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 389-398. | 1.5 | 17 |
| 35 | Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5351-5363. | 7.0 | 57 |
| 36 | Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131. | | 64 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 165-174. | 3.8 | 123 |
| 38 | Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunology Research, 2019, 7, 1025-1035. | 3.4 | 70 |
| 39 | Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status. Head and Neck, 2019, 41, 2636-2646. | 2.0 | 20 |
| 40 | Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. Cancer Cell, 2019, 35, 588-602.e10. | 16.8 | 636 |
| 41 | Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice. Blood Advances, 2019, 3, 3080-3091. | 5.2 | 22 |
| 42 | Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nature Cell Biology, 2019, 21, 190-202. | 10.3 | 384 |
| 43 | Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 2018, 24, 541-550. | 30.7 | 3,421 |
| 44 | TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell, 2018, 33, 60-74.e6. | 16.8 | 270 |
| 45 | Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 2018, 359, 97-103. | 12.6 | 3,126 |
| 46 | Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. , 2018, 6, 118. | | 43 |
| 47 | Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell, 2018, 34, 561-578.e6. | 16.8 | 113 |
| 48 | Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. , 2018, 6, 98. | | 43 |
| 49 | Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Science Advances, 2018, 4, eaat7828. | 10.3 | 203 |
| 50 | Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity, 2018, 49, 178-193.e7. | 14.3 | 502 |
| 51 | Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. Cell Reports, 2017, 19, 203-217. | 6.4 | 454 |
| 52 | Surgical Procedures and Methodology for a Preclinical Murine Model of Mammary Cancer Metastasis. Journal of Visualized Experiments, 2017, . | 0.3 | 5 |
| 53 | Immune Escape in Breast Cancer During <i>In Situ</i> to Invasive Carcinoma Transition. Cancer Discovery, 2017, 7, 1098-1115. | 9.4 | 185 |
| 54 | Trim32 Deficiency Enhances Th2 Immunity and Predisposes to Features of Atopic Dermatitis. Journal of Investigative Dermatology, 2017, 137, 359-366. | 0.7 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Alk5 inhibition increases delivery of macromolecular and protein-bound contrast agents to tumors. JCI Insight, 2016, 1, . | 5.0 | 13 |
| 56 | MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment. Nature Communications, 2016, 7, 13597. | 12.8 | 54 |
| 57 | Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer. Cancer Discovery, 2016, 6, 22-35. | 9.4 | 69 |
| 58 | Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology, 2016, 5, e1136044. | 4.6 | 55 |
| 59 | The Basis of Oncoimmunology. Cell, 2016, 164, 1233-1247. | 28.9 | 671 |
| 60 | Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discovery, 2016, 6, 270-285. | 9.4 | 408 |
| 61 | Senescence and cancer: An evolving inflammatory paradox. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 14-22. | 7.4 | 35 |
| 62 | Sustained Endothelial Expression of HoxA5 In Vivo Impairs Pathological Angiogenesis And Tumor Progression. PLoS ONE, 2015, 10, e0121720. | 2.5 | 20 |
| 63 | TH2-Polarized CD4+ T Cells and Macrophages Limit Efficacy of Radiotherapy. Cancer Immunology Research, 2015, 3, 518-525. | 3.4 | 197 |
| 64 | Macrophages and Therapeutic Resistance in Cancer. Cancer Cell, 2015, 27, 462-472. | 16.8 | 1,130 |
| 65 | Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance. Trends in Cancer, 2015, 1, 66-75. | 7.4 | 101 |
| 66 | Duality of the Immune Response in Cancer: Lessons Learned from Skin. Journal of Investigative Dermatology, 2014, 134, E23-E28. | 0.7 | 23 |
| 67 | Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. Cancer Cell, 2014, 26, 623-637. | 16.8 | 751 |
| 68 | Manipulating MicroRNAs to Regulate Macrophage Polarization in Gliomas. Journal of the National Cancer Institute, 2014, 106, dju230-dju230. | 6.3 | 6 |
| 69 | A Listeria Vaccine and Depletion of T-Regulatory Cells Activate Immunity Against Early Stage Pancreatic Intraepithelial Neoplasms and Prolong Survival of Mice. Gastroenterology, 2014, 146, 1784-1794.e6. | 1.3 | 118 |
| 70 | B cells and their mediators as targets for therapy in solid tumors. Experimental Cell Research, 2013, 319, 1644-1649. | 2.6 | 63 |
| 71 | Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?. Science, 2013, 339, 286-291. | 12.6 | 943 |
| 72 | CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 ⁺ T cells. Oncoimmunology, 2013, 2, e26968. | 4.6 | 311 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Leukocyte composition of human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2796-2801. | 7.1 | 393 |
| 74 | Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment. Cancer Cell, 2012, 21, 309-322. | 16.8 | 3,578 |
| 75 | Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery, 2011, 1, 54-67. | 9.4 | 1,486 |